

Supplementary Materials: Clinical Efficacy and Safety of Sodium Thiosulfate in the Treatment of Uremic Pruritus: A Meta-Analysis of Randomized Controlled Trials

Ping-Hsun Lu, Hui-En Chuo, Ko-Lin Kuo, Jian-Fu Liao and Po-Hsuan Lu

Table S1. Grade profile summary of ‘STS for UP’ Quality assessment

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pruritus scores	placebo	Relative (95% CI)	Absolute (95% CI)		
pruritus scores												
4	randomised trials	serious	serious	not serious	not serious	publication bias strongly suspected	111	111	-	SMD 3.52 lower (5.63 lower to 1.41 lower)	⊕○○○ VERY LOW	IMPORTANT
Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	PSQI	placebo	Relative (95% CI)	Absolute (95% CI)		

Pittsburgh sleep quality index

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pruritus scores	placebo	Relative (95% CI)	Absolute (95% CI)		
2	randomised trials	serious	not serious	not serious	not serious	publication bias strongly suspected	58	58	-	MD 4.7 lower (4.93 lower to 4.48 lower)	⊕⊕○○ LOW	IMPORTANT

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Effective rate	placebo	Relative (95% CI)	Absolute (95% CI)		

Effective rate

2	randomised trials	serious	not serious	not serious	not serious	publication bias strongly suspected	50/53 (94.3%)	27/53 (50.9%)	OR 18.52 (4.94 to 69.38)	441 more per 1,000 (from 327 more to 477 more)	⊕⊕○○ LOW	IMPORTANT
---	-------------------	---------	-------------	-------------	-------------	-------------------------------------	---------------	---------------	--------------------------	--	-------------	-----------

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	ADR	placebo	Relative (95% CI)	Absolute (95% CI)		

Adverse drug reaction

3	randomised trials	serious	serious	not serious	serious	publication bias strongly suspected	9/83 (10.8%)	3/83 (3.6%)	RR 2.44 (0.37 to 15.99)	52 more per 1,000 (from 23 fewer to 542 more)	⊕○○○ VERY LOW	IMPORTANT
---	-------------------	---------	---------	-------------	---------	-------------------------------------	--------------	-------------	-------------------------	---	------------------	-----------

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Lab	placebo	Relative (95% CI)	Absolute (95% CI)		

Serum creatinine

2	randomised trials	not serious	very serious	not serious	serious	publication bias strongly suspected	51	51	-	MD 63.49 lower (256.36 lower to 129.38 higher)	⊕○○○ VERY LOW	IMPORTANT
---	-------------------	-------------	--------------	-------------	---------	-------------------------------------	----	----	---	--	------------------	-----------

Blood urea nitrogen

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Lab	placebo	Relative (95% CI)	Absolute (95% CI)		
2	randomised trials	not serious	very serious	not serious	serious	publication bias strongly suspected	51	51	-	MD 2.4 lower (8.58 lower to 3.79 higher)	⊕○○○ VERY LOW	IMPORTANT

Albumin

2	randomised trials	not serious	not serious	not serious	serious	publication bias strongly suspected	58	58	-	MD 2.99 lower (5.13 lower to 0.86 lower)	⊕⊕○○ LOW	IMPORTANT
---	-------------------	-------------	-------------	-------------	---------	-------------------------------------	----	----	---	--	-------------	-----------

Calcium

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Lab	placebo	Relative (95% CI)	Absolute (95% CI)		
2	randomised trials	not serious	serious	not serious	serious	publication bias strongly suspected	51	51	-	MD 0.22 lower (0.56 lower to 0.13 higher)	⊕○○○ VERY LOW	IMPORTANT

Phosphorus

2	randomised trials	not serious	serious	not serious	serious	publication bias strongly suspected	51	51	-	MD 0.14 lower (0.58 lower to 0.3 higher)	⊕○○○ VERY LOW	IMPORTANT
---	-------------------	-------------	---------	-------------	---------	-------------------------------------	----	----	---	--	------------------	-----------

Parathyroid hormone

Certainty assessment							Nº of patients		Effect		Certainty	Importance
Nº of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Lab	placebo	Relative (95% CI)	Absolute (95% CI)		
2	randomised trials	not serious	serious	not serious	serious	publication bias strongly suspected	51	51	-	MD 22.2 lower (84.35 lower to 39.95 higher)	⊕○○○ VERY LOW	IMPORTANT

CI: confidence interval; MD: mean difference; OR = odds ratio; RR = risk ratio; STS = sodium thiosulphate; UP = uremic pruritus.